MITSUI MEMORIAL HOSPITAL

Olomorasib Plus Pembrolizumab Shows Promise in KRAS G12C-Mutated NSCLC

8 months ago

• Olomorasib combined with pembrolizumab demonstrated a 77% overall response rate in first-line NSCLC patients with KRAS G12C mutations, regardless of PD-L1 expression. • In previously treated NSCLC patients, the combination therapy achieved a 40% overall response rate and an 88% disease control rate. • Common adverse events included diarrhea, fatigue, and increased ALT levels, with manageable safety profiles observed across both cohorts. • A global registrational trial, SUNRAY-01 (NCT06119581), is underway to further evaluate the combination in first-line KRAS G12C-mutated NSCLC.